WHO meeting sees top experts discuss pneumococcal disease

27 February 2006

The need for an urgent and sustained effort to document the burden of pneumococcal disease formed the core of discussions amongst leading scientists attending a World Health Organization meeting this month. With pneumococcal disease estimated to be responsible for up to one million child deaths each year - local efforts to measure the scale of the problem in Asia are essential in preventing unnecessary child deaths from Streptococcus pneumoniae, a bacterium that causes pneumonia and meningitis.

Serious pneumococcal infections occur throughout life, but young children (especially those under two years old) and the elderly are at the highest risk for severe disease. Furthermore, over 90% of pneumococcal pneumonia deaths in children occur in developing countries, and pneumococcal meningitis kills or disables over 40% of the children who get the disease.

"Effective surveillance of pneumococcal disease and its serotypes is needed to accurately map the magnitude of the problem and help evaluate the impact of available vaccines," commented Thomas Cherian, coordinator ai, EPI+, Vaccines and Biologicals at the WHO.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight